Q1 Earnings Forecast for CRBU Issued By Leerink Partnrs

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Caribou Biosciences in a report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($0.48) per share for the quarter. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($1.82) EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million for the quarter, compared to analysts' expectations of $2.11 million.

CRBU has been the topic of a number of other research reports. Bank of America cut their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $10.33.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded up $0.01 during midday trading on Friday, reaching $0.85. 568,551 shares of the company's stock traded hands, compared to its average volume of 1,557,184. The stock has a 50 day moving average of $1.01 and a 200-day moving average of $1.56. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $4.21. The company has a market cap of $78.82 million, a PE ratio of -0.51 and a beta of 2.36.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. purchased a new position in Caribou Biosciences during the first quarter valued at $559,000. Exchange Traded Concepts LLC lifted its stake in shares of Caribou Biosciences by 51.4% in the first quarter. Exchange Traded Concepts LLC now owns 124,889 shares of the company's stock worth $114,000 after buying an additional 42,395 shares in the last quarter. Milestone Asset Management LLC grew its holdings in shares of Caribou Biosciences by 100.9% during the first quarter. Milestone Asset Management LLC now owns 329,090 shares of the company's stock valued at $300,000 after buying an additional 165,301 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in Caribou Biosciences by 138.8% in the 1st quarter. Green Alpha Advisors LLC now owns 432,325 shares of the company's stock worth $395,000 after acquiring an additional 251,271 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in Caribou Biosciences in the 4th quarter worth approximately $222,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.